Therapy for pneumococcal infection at the millennium: Doubts and certainties

American Journal of Medicine

Volumn 107, Issue 1 A, 1999, Pages 77-85

  Ball, Peter ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CEFTRIAXONE; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; GREPAFLOXACIN; IMIPENEM; KETOLIDE; LEVOFLOXACIN; MOXIFLOXACIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN; VANCOMYCIN;

BACTEREMIA; BACTERIAL MENINGITIS; BACTERIUM ISOLATE; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; OTITIS MEDIA; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

EID: 0033606787     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(99)00104-7     Document Type: Conference Paper

References (97)

1. Austrian R., Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med. 60:1964;759-776.
2. Fine M.J., Singer D.E., Hanusa B.H., et al. Validation of pneumonia prognostic index using the MedisGroups comparative hospital database. Am J Med. 94:1993;153-159.
3. Tilghman R.C., Finland M. Clinical significance of bacteremia in pneumococcal pneumonia. Arch Intern Med. 59:1937;602-619.
4. Mufson M.A., Kruss D.M., Wasil R.E., Metzeger W.I. Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era. Arch Intern Med. 134:1974;505-510.
5. Mularczyk M, Leophonte P, Rouquet RM, and the French Study Group for Pneumonia. A prospective hospital study of 363 pneumococcal pneumonia cases in adults. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario, Canada. Abstract K-94.
6. Osler W. The Principles and Practice of Medicine. 4th ed. 1901;108 Appleton, New York.
7. Austrian R. Random gleanings from a life with the pneumococcus. J Infect Dis. 131:1975;474-484.
8. Pallares R., Liñares J., Vadillo, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 333:1995;474-480.
9. Friedland I.R. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Paediatr Infect Dis J. 14:1995;885-890.
10. Goldstein F.W., Garau J. 30 years of penicillin-resistant S pneumoniae myth or reality . Lancet. 350:1997;233-234.
11. Watson DA, Musher DM, Jacobson JW, Verhoef J. A brief history of the pneumococcus in biomedical research: a panoply of scientific discovery. Clin Infect Dis 193;17:913-924.
12. Whitby L.E.H. Chemotherapy of pneumococcal and other infections with 2-(p-aminobenzene sulphonamido) pyridine. Lancet. 1:1938;1210-1212.
13. Fleming A. On the antibacterial action of cultures of a penicillium with special reference to their useful isolation of B. influenzae. Br J Exp Pathol. 10:1929;226-236.
14. Chain E., Jennings M.A., Florey H.W., et al. Penicillin as a chemotherapeutic agent. Lancet. 2:1940;226-228.
15. Abraham E.P., Gardner A.D., Chain E., et al. Further observations on penicillin. Lancet. 2:1941;177-189.
16. McKee C.M., Houck C.L. Induced resistance to penicillin of cultures of staphylococci, pneumococci and streptococci. Proc Soc Exp Biol Med. 53:1943;33-34.
17. Schmidt L.H., Sesler C.L. Development of resistance to penicillin by pneumococci. Proc Soc Exp Biol Med. 52:1943;353-357.
18. Hansman D., Bullen M.M. A resistant pneumococcus. Lancet. 2:1967;264-265.
19. Hansman D., Glasgow H., Sturt J., et al. Increased resistance to penicillin of pneumococci isolated from man. N Engl J Med. 284:1971;175-177.
20. Appelbaum P.C., Koornhof H.J., Jacobs M., et al. Multiple-antibiotic resistance of pneumococci South Africa . MMWR. 26:1977;285-286.
21. Liñares J., Pallares R., Alonso T., et al. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). Clin Infect Dis. 15:1992;99-105.
22. Doern G.V. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med. 99:1995;3S-7S.
23. Jacobs M.R. Respiratory tract infection epidemiology and surveillance . J Chemother. 9:(suppl 3):1997;10-17.
24. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in S. pneumoniae (Sp), H. influenzae (Hi) and M. catarrhalis (Mc) in the US during the 1996-97 respiratory season. In: Program and abstracts of the 35th Annual Conference of the Infectious Diseases Society of America; 1997; San Francisco, Ca. Abstract 52.
25. Soares S., Kristinsson K.G., Musser J.M., Tomasz A. Evidence for the introduction of a multi-resistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s. J Infect Dis. 168:1993;158-163.
26. Baquero F. Trends in antibiotic resistance of respiratory pathogens an analysis and commentary on a collaborative surveillance study . J Antimicrob Chemother. 38:(suppl A):1996;117-132.
27. Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis. 24:(suppl 1):1997;S85-S88.
28. Kristinsson K.G. Epidemiology of penicillin-resistant pneumococci in Iceland. Microb Drug Res. 1:1995;121-125.
29. Lyon D.J., Scheel O., Fung K.S.C., Chen A.F.B., Henrichsen J. Rapid emergence of penicillin-resistant pneumococci in Hong Kong. Scand J Infect Dis. 28:1996;375-376.
30. Torres L, Pelaez T, Vasallo FJ, et al. Evolution of antibiotic resistance of Streptococcus pneumoniae: increase of penicillin resistance in blood and cerebrospinal fluid (CSF) isolates. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario, Canada. Abstract C-168.
31. Baquero F., Negri M.C. Strategies to minimize the development of antibiotic resistance. J Chemother. 9:1996;29-37.
32. Finland M. Emergence of antibiotic resistance in hospitals, 1935-1975. Rev Infect Dis. 1:1979;4-21.
33. Kristinsson K.G. Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci. Microb Drug Res. 3:1997;117-123.
34. Reichmann P., Koenig A., Liñares J., et al. A global gene pool for high level cephalosporin resistance in commensal Streptococcus species and Streptococcus pneumoniae. J Infect Dis. 176:1997;1001-1002.
35. English R.M., Badcock J.C., Giay T., et al. Effect of nutrition improvement project on morbidity from infectious diseases in pre-school children in Vietnam comparison with control commune . Br Med J. 315:1997;1122-1125.
36. Reichler M.R., Allphin A.A., Breiman R.F., et al. Spread of multiply resistant Streptococcus pneumoniae at a day-care center in Ohio. J Infect Dis. 166:1992;1346-1353.
37. Reichler M.R., Rakovsky J., Slacikova M., et al. Spread of multi-drug resistant Streptococcus pneumoniae among hospitalized children in Slovakia. J Infect Dis. 173:1996;374-379.
38. Block S.L., Harrison C.J., Hedrick J.A., et al. Penicillin-resistant Streptococcus pneumoniae in acute otitis media risk factors, susceptibility patterns and antimicrobial management . Paediatr Infect Dis J. 14:1995;751-759.
39. Radetsky M.S., Johansen T.L., Lauer B.A., et al. Multiply resistant pneumococcus causing meningitis its epidemiology within a day care centre . Lancet. 2:1981;771-773.
40. Boken D.J., Chartrand S.A., Goering R.V., et al. Colonisation with pencillin-resistant Streptococcus pneumoniae in a child-care center. Paediatr Infect Dis J. 14:1995;879-884.
41. Guidelines for the initial management of adults with community acquired pneumonia diagnosis, assessment of severity and initial antimicrobial therapy . Am Rev Respir Dis. 148:1993;1418-1426.
42. Guidelines for the management of community acquired pneumonia in adults admitted to hospital. Br J Hosp Med. 49:1993;346-350.
43. Stool S.E., Field M.J. The impact of otitis media. Pediatr Infect Dis J. 8:1989;1-84.
44. Poole M.D. Otitis media complications and treatment failures implications of pneumococcal resistance . Pediatr Infect Dis J. 14:1995;S23-S26.
45. Craig W.A., Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J. 15:1996;255-259.
46. Hoberman A., Paradise J.L., Block S., et al. Efficacy of amoxicillin/clavulanate for acute otitis media relation to Streptococcus pneumoniae susceptibility . Pediatr Infect Dis J. 15:1996;955-962.
47. Dowell S.F., Butler J.C., Giebink G.S., et al. Acute otitis media management and surveillance in the era of pneumococcal resistance - a report from the DRSP Therapeutic Working Group . Pediatr Infect Dis J. 18:1999;1-9.
48. Gehanno P., Lenoir G., Berche P. In vivo correlates for Streptococcus pneumoniae penicillin resistance in acute otitis media. Antimicrob Agents Chemother. 39:1995;271-272.
49. Barry B., Gehanno P., Blumen M., Boucot I. Clinical outcome of acute otitis media caused by pneumococci with decreased susceptibility to penicillin. Scand J Infect Dis. 26:1994;446-452.
50. Dagan R., Abramson O., Leibowitz E., et al. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Pediatr Infect Dis J. 15:1996;980-985.
51. Klugman K.P., Koornhof H.J. Penicillin-resistant pneumococcal meningitis. Lancet. 350:1997;1176. (Letter.).
52. Ball P. The changing scene in serious infections the role of ceftriaxone . Br J Intens Care. suppl 1:1993;13-17.
53. Schaad U.B., Suter S., Gianella-Borradori A., et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med. 322:1990;141-147.
54. Tan T.Q., Schutze G.E., Mason E.O., Kaplan S.L. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad spectrum cephalosporins. Antimicrob Agents Chemother. 38:1994;918-923.
55. Paris M.M., Ramilo O., McCracken G.H. Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother. 39:1995;2171-2175.
56. Therapy for children with invasive pneumococcal disease. Pediatrics. 99:1997;289-299.
57. Munoz M., Valderrabanos E.S., Diaz E., et al. Appearance of resistance to beta-lactam antibiotics during therapy for Streptococcus pneumoniae meningitis. J Pediatr. 127:1995;98-99.
58. Bradley J.S., Scheld W.M. The challenge of penicillin-resistant Streptococcus pneumoniae meningitis current antibiotic therapy in the 1990s . Clin Infect Dis. 24:(suppl 2):1997;S213-S221.
59. Klugman K.P., Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Antimicrob Agents Chemother. 39:1995;1140-1146.
60. Pikis A., Donkersloot J.A., Akram S., et al. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 40:1997;105-108.
61. Friedland I.R., Klugman K.P. Failure of chloramphenicol therapy in penicillin-resistant pneumococal meningitis. Lancet. 339:1992;405-408.
62. Paris M.M., Hickey S.M., Trujillo M., et al. Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin and cephalosporin resistant pneumococcal meningitis. Antimicrob Agents Chemother. 39:1995;1243-1246.
63. Ostergaard C, Sorensen TK, Knudsen JD, Frimodt-Møller N. Evaluation of a new quinolone, Bay 12-8039, against penicillin resistant Streptococcus pneumoniae, type 9V in experimental meningitis in rabbits. In: Programs and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario, Canada. Abstract B-77.
64. Trostdorf F, Reinert RR, Schmidt H, et al. RPR 59500 for experimental pneumococcal meningitis. In: Programs and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario, Canada. Abstract B-78.
65. Baughman R, and the US Synercid CAP Study Group. Randomized, double-blind, comparative, multicenter study of quinupristin-dalfopristin (Q/D, RPR59500, Synercid) versus combination of ceftriaxone and erythromycin in the treatment of acute community-acquired bacterial pneumonia (CAP). In: Programs and abstracts of the 20th International Congress of Chemotherapy; 1997; Sydney, Australia. Abstract 2321.
66. Schentag J.J., Nix D.E., Adelman M.H. Mathematical elimination of dual individualization principles (I) relationship between AUIC above MIC and area under the elimination curve for cefmenoxime, ciprofloxacin and tobramycin . Drug Intell Clin Pharm. 25:1991;1050-1057.
67. Forrest A., Nix D.E., Ballow C.H., et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 37:1993;1073-1081.
68. Goss T.F., Forrest A., Nix D.E., Ballow C.H., et al. Mathematical elimination of dual individualisation principles (II) the rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime . Ann Pharmacother. 28:1994;863-868.
69. Ball P., Tillotson G.S. Lower respiratory tract infection the role of ciprofloxacin . J Int Med Res. 23:1995;315-327.
70. File T.M., Segreti J., Dunbar L., et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community acquired pneumonia. Antimicrob Agents Chemother. 41:1997;1965-1972.
71. Baldwin D.R., Honeybourne D., Wise R. Pulmonary disposition of antimicrobial agents in vivo observations and clinical significance . Antimicrob Agents Chemother. 36:1992;1176-1180.
72. Ball P. The quinolones history and overview . Andriole V.T. The Quinolones. 2nd ed. 1998;1-28 Academic Press, New York.
73. Davies B.I., Maesen F.P.V. Quinolones in chest infections. J Antimicrob Chemother. 18:1986;296-299.
74. Lee B.L., Padula A.M., Kimbrough R.C., et al. Infectious complications with respiratory pathogens despite ciprofloxacin. N Engl J Med. 325:1991;520-521.
75. Leeper K.V., Jones A.M., Tillotson G.S. The changing bacterial aetiology of chronic obstructive pulmonary disease (COPD). Chest. 112:1997;21S. (Abstr.).
76. Fink M.P., Snydman D.R., Niedreman M.S., et al. Treatment of severe pneumonia in hospitalized patients results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin . Antimicrob Agents Chemother. 38:1994;547-557.
77. Jardim J.R. Consenso latinamerico sobre infecciones en bronquitis cronica. Rev Panam Infect. 1:1997;3-19.
78. Brueggemann A.B., Kugler K.C., Doern G.V. In vitro activity of Bay 12 8039, a novel 8-methoxy quinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother. 41:1997;1594-1597.
79. Aubier M., Lode H., Gialdroni-Grassi G., et al. Sparfloxacin for the treatment of community-acquired pneumonia a pooled data analysis of two studies . J Antimicrob Chemother. 37:(suppl A):1996;73-82.
80. Örtqvist Å., Valtonen M., Cars O., et al. Oral empiric treatment of community acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. Chest. 110:1996;1499-1506.
81. Jaillon P., Morganroth J., Brumpt I., et al. Overview of electrocardiographic and cardiovascular safety for sparfloxacin. J Antimicrob Chemother. 37:(suppl A):1996;161-167.
82. Topkis S., Swarz H., Breisch S.A., Maroli A.N. Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community acquired pneumonia. Clin Ther. 19:1997;975-988.
83. Patel T, Desai R, Duff J, et al. Comparison of grepafloxacin (GFX) with clarithromycin in the treatment of community acquired pneumonia (CAP). In: Programs and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario, Canada. Abstract LM-69.
84. Mandell L, Williams-Hopkins D, Hopkins S. Efficacy of trovafloxacin in patients with community acquired pneumonia due to penicillin susceptible and resistant S. pneumoniae. In: Programs and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario, Canada. Abstract LM-71.
85. Niederman M, Traub S, Ellison WT, et al. A double blind, randomized, multicenter, global study in hospitalised community acquired pneumonia (CAP) comparing trovafloxacin with ceftriaxone-erythromycin. In: Programs and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario, Canada. Abstract LM-72.
86. Petipretz P, Bronco Pines JB, Dosedel J, Rico Mendez G, Arvis P. Moxifloxacin (MFX) versus amoxycillin (AMOX) in the treatment of community-acquired suspected pneumococcal pneumonia: a multi-national double-blind randomized study. 9th European Congress of Clinical Microbiology and Infectious Diseases. Berlin, March 1999, Abstract P 207.
87. Krasemann C, Meyer JM, Springsklee M. Moxifloxacin (MFX) in community-acquired pneumonia (CAP) - a bacteriologic and clinical meta-analysis. 9th European Congress of Clinical Microbiology and Infectious Diseases. Berlin, March 1999. Abstract P 205.
88. Potgeiter P.D., Hammond J.M.J. The intensive care management, mortality and prognostic factors in severe community acquired pneumococcal pneumonia. Intens Care Med. 22:1996;1301-1306.
89. Macfarlane J., Holmes W., Macfarlane R., Britten N. Influence of patients expectations on antibiotic management of acute lower respiratory illness in general practice questionnaire study . BMJ. 315:1997;1211-1214.
90. Spangler S.K., Jacobs M.R., Appelbaum P.C. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766) and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother. 40:1996;481-484.
91. Klugman K., Wasas A. In vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 36:1995;873-874.
92. Felmingham D., Gruneberg R.N. A multicentre collaborative study of the antimicrobial susceptibility of community acquired, lower respiratory tract pathogens 1992-1993 the Alexander Project . J Antimicrob Chemother. 38:(suppl A):1996;1-57.
93. Pankuch G.A., Jacobs M.R., Appelbaum P.C. Activity of DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and OPC-17116 against 112 penicillin-susceptible and resistant pneumococci. Drugs. 49:(suppl 2):1995;235-237.
94. Appelbaum P.C. Emerging resistance to antimicrobial agents in Gram-positive bacteria. Drugs. 51:(suppl 1):1996;1-5.
95. Dalhoff A., Petersen U., Endermann R. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Chemotherapy. 42:1996;410-425.
96. Barry A.L., Fuchs P.C. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin. J Chemother. 9:1997;9-16.
97. Wilson W.R., Bouza E., Lode H., Mouton Y. The use of cefotaxime for the treatment of common infections in vitro, pharmacokinetic and clinical considerations . J Chemother. 9:(suppl 2):1997;5-18.